Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
OR

NASDAQ · ORMP

Oramed Pharmaceuticals Inc.

Healthcare · Biotechnology

$4.81

Up+$0.02 (+0.42%)

Updated Aug 23, 2026, 12:34 PM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
126.46M
P/E ratio
-5.24
Dividend yield
5.20%
52-week range
$3.15 – $5.19
Volume
126.13K
Avg. volume
162.09K

Price performance

ORMP price history

1M range · 0 trading sessions · Daily adjusted prices

ORMP does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ORMP news

The latest Smart Investors Daily articles mentioning ORMP.

Stock researchCompany · Overview

ORMP research

Overview

Company profile and research snapshot.

Company profile

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ORMP recent ratings
DateFirmRatingTarget
Sep 9, 2024HC Wainwright & Co.Neutral—
May 20, 2024HC Wainwright & Co.Neutral—
May 17, 2023Canaccord GenuityHold—
Jan 17, 2023HC Wainwright & Co.Neutral—
Jan 12, 2023Canaccord GenuityHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jun 25, 2026

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).

Benzinga · Jun 25, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out

Yahoo · Jun 18, 2026

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT ORMP shares to be added to the Russell 2000® & Russell 3000® As Oramed Pharmaceuticals (NASDAQ: ORMP) transitions its business model to leverage its strong balance sheet and allocate capital to investments in the biomedical and other areas, the company announced that its shares will be added to the U.S. small-cap Russell 2000® and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By